Roche Holding AG said an experimental breast-cancer treatment will get an expedited review from US regulators after showing it helped patients live longer without the disease progressing.

(Reuters) - Health regulators granted a priority review for an experimental Roche breast cancer drug that in clinical trials added six months to the time before the disease worsened. The Food and ...

The Food and Drug Administration has issued a positive review of a breast cancer drug from Roche that could soon become the first pharmaceutical option approved for treating early-stage disease ...

Two months after Roche unveiled clinical trial data that could help bring its breast cancer drug Kadcyla to early-stage patients, the company has won a speedy FDA review. And if Roche succeeds, it ...

Roche RHHBY announced that the FDA has approved pipeline candidate, inavolisib, for the treatment of breast cancer, under the brand name Itovebi. The drug is approved in combination with Pfizer ...

FDA rewards Roche with priority review for blockbuster cancer drug By John Carroll Feb 8, 2012 8:15am Biotech ...

WASHINGTON (AP) — The Food and Drug Administration has issued a positive review of a breast cancer drug from Roche that could soon become the first pharmaceutical option approved for treating ...

The FDA said women who received the drug Perjeta had fewer tumors. Hotspots ranked Start the day smarter ... FDA: Drug works in early-stage breast cancer. Matthew Perrone. Associated Press.

FDA pertuzumab U.S. approval decision due by June 8 Drug is used with Herceptin in HER2-positive patients Roche shares up 1.9 percent Feb 7 (Reuters) - U.S. health regulators granted a priority ...